{"url_path":"/sec/fbrx/8-k/2026-06-02/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-02","source_url":"https://www.sec.gov/Archives/edgar/data/1419041/0001193125-26-253436-index.html","accession_number":"0001193125-26-253436","cik":"0001419041","ticker":"FBRX","issuer_name":"Forte Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1419041/0001193125-26-253436-index.html","primary_entity_key":"0001419041","primary_entity_name":"Forte Biosciences, Inc."},"word_count":292,"has_tables":true,"body_markdown":"Item 5.07.\n\nSubmission of Matters to a Vote of Security Holders.\n\nThe Company held its 2026 annual meeting of stockholders on May 29, 2026 (the “Annual Meeting”). Of the 20,478,817 Shares outstanding as of the record date of April 17, 2026, 17,766,034 Shares were represented at the Annual Meeting, either by proxy or by attending the meeting. The matters voted on at the Annual Meeting and the votes cast with respect to each such matter are set forth below:\n\n \n\n1.\n\nElection of Class III Directors. The following nominees were elected to serve as Class III directors, each to hold office until the Company’s 2029 annual meeting of stockholders or until his respective successor has been duly elected and qualified or his or her earlier resignation or removal:\n\n \n\nNominee\n  \nVotes For\n \n  \nVotes Withheld\n \n  \nBroker Non-Votes\n \n\nSteven Kornfeld\n\n  \n \n12,286,043\n \n  \n \n3,973,928\n \n  \n \n1,506,063\n \n\nScott Brun, M.D.\n\n  \n \n12,958,889\n \n  \n \n3,301,082\n \n  \n \n1,506,063\n \n\nPaul A. Wagner, Ph.D.\n\n  \n \n16,027,110\n \n  \n \n232,861\n \n  \n \n1,506,063\n \n\n \n\n2.\n\nRatification of Appointment of Independent Registered Public Accounting Firm. The appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified based on the following results of voting:\n\n \n\nVotes For\n\n \n\nVotes Against\n\n \n\nAbstentions\n\n \n\nBroker Non-Votes\n\n17,722,893\n \n3,182\n \n39,959\n \n\n0\n\n \n\n3.\n\nAdvisory Vote on Executive Compensation. The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers for the fiscal year ended December 31, 2025. The votes regarding the proposal were as follows:\n\n \n\nVotes For\n\n \n\nVotes Against\n\n \n\nAbstentions\n\n \n\nBroker Non-Votes\n\n12,143,153\n \n3,764,729\n \n352,089\n \n1,506,063\n\n \n\n4.\n\nApproval of the Amended and Restated 2021 Equity Incentive Plan. The Company’s stockholders approved the A&R 2021 Equity Incentive Plan. The votes regarding the proposal were as follows:\n\n \n\nVotes For\n\n \n\nVotes Against\n\n \n\nAbstentions\n\n \n\nBroker Non-Votes\n\n11,911,879\n \n3,997,050\n \n351,042\n \n1,506,063"}